Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index; 19 of the 65 sources its claims cite were checked for support.
Abstract
Aggregation of amyloid-β (Aβ) as toxic oligomers and amyloid plaques within the brain appears to be the pathogenic event that initiates Alzheimer's disease (AD) lesions. One therapeutic strategy has been to reduce Aβ levels to limit its accumulation. Activation of certain neurotransmitter receptors can regulate Aβ metabolism. We assessed the ability of serotonin signaling to alter brain Aβ levels and plaques in a mouse model of AD and in humans. In mice, brain interstitial fluid (ISF) Aβ levels were decreased by 25% following administration of several selective serotonin reuptake inhibitor (SSRI) antidepressant drugs. Similarly, direct infusion of serotonin into the hippocampus reduced ISF Aβ levels. Serotonin-dependent reductions in Aβ were reversed if mice were pretreated with inhibitors of the extracellular regulated kinase (ERK) signaling cascade. Chronic treatment with an SSRI, citalopram, caused a 50% reduction in brain plaque load in mice. To test whether serotonin signaling could impact Aβ plaques in humans, we retrospectively compared brain amyloid load in cognitively normal elderly participants who were exposed to antidepressant drugs within the past 5 y to participants who were not. Antidepressant-treated participants had significantly less amyloid load as quantified by positron emission tomography (PET) imaging with Pittsburgh Compound B (PIB). Cumulative time of antidepressant use within the 5-y period preceding the scan correlated with less plaque load. These data suggest that serotonin signaling was associated with less Aβ accumulation in cognitively normal individuals.
Overview
CoChat Summary
TL;DR
Serotonin signaling, including via SSRI antidepressants, acutely lowers brain interstitial fluid amyloid-β (Aβ) in a mouse model of Alzheimer’s disease through an ERK-dependent mechanism and chronically reduces plaque burden. In cognitively normal older adults, retrospective antidepressant use within the past 5 years was associated with lower Pittsburgh Compound B PET amyloid load.
Key findings
- In PS1APP mice, SSRIs fluoxetine, desvenlafaxine, and citalopram reduced interstitial fluid (ISF) Aβ by 25% at 24 h; citalopram at 5 and 10 mg/kg reduced ISF Aβ by 16% and 26%, respectively. Direct hippocampal serotonin infusion reduced ISF Aβ by 35% over 8 h without changing Aβ elimination half-life (~1 h).
- ERK signaling was required: MEK/ERK inhibitors increased ISF Aβ by 40% and blocked citalopram’s Aβ-lowering effect; citalopram increased activated pERK2 and α-secretase activity.
- Chronic citalopram (8 mg/kg/day for 4 months) reduced cortical and hippocampal plaque load by 62% and 50%, respectively, and reduced CSF Aβ40 and Aβ42 by 28% and 55%.
- In 186 cognitively normal participants, those treated with antidepressants within the past 5 years (mean exposure 34.5 months) had lower mean cortical binding potential (0.06 ± 0.023) than untreated participants (0.13 ± 0.019; Wilcoxon rank sum P = 0.01), and longer antidepressant duration correlated with lower amyloid load (ρ = −0.298, P = 0.02).
Methods
- Mouse studies used 2- to 3-month-old and 12-month-old PS1APP transgenic mice with unilateral hippocampal microdialysis to measure ISF Aβ dynamically; drugs were given i.p. or by reverse microdialysis, with ELISA, histology, enzymatic activity assays, and quantitative PCR.
- Chronic mouse treatment began at 3 months of age with vehicle or citalopram in drinking water for 4 months, followed by histological plaque quantification and biochemical Aβ measurements.
- Human study retrospectively compared 186 cognitively normal participants (CDR = 0) who underwent Pittsburgh Compound B PET amyloid imaging; antidepressant exposure within the past 5 years was assessed by structured interview, and treated vs untreated groups were compared with Wilcoxon rank-sum tests and Spearman correlation.
Limitations
- The paper states that the findings are preliminary and unreplicated, and that a randomized controlled clinical trial would be needed to determine whether SSRIs have a beneficial effect on cerebral amyloid burden in humans.
- The paper states that the retrospective human study could not separate the effects of antidepressant exposure from depression itself, and that excluding participants with CDR greater than zero may have produced selection bias.
- The paper states that a direct causal relation between antidepressants and plaque reduction in humans remains to be demonstrated; the human evidence is observational and retrospective.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 22 Not checked · 66 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Activation of select 5HT-Rs increases nonamyloidogenic processing of APP in vitro (14–16)”
What the sources say
- Supportedcites [14] Nitsch RM, Deng M, Growdon JH, Wurtman RJ. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem. 1996;271:4188–4194. doi: 10.1074/jbc.271.8.4188. [DOI] [PubMed] [Google Scholar] source
The paper’s opening summary states that non-amyloidogenic APP processing produces secreted APPs and that serotonin increased APPs release three- to fourfold in 3T3 cells expressing 5-HT2a or 5-HT2c receptors. The Discussion likewise identifies stimulation of these receptors as increasing APPs secretion. The supplied copy gives no page numbers for these passages. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [15] Arjona AA, Pooler AM, Lee RK, Wurtman RJ. Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Res. 2002;951:135–140. doi: 10.1016/s0006-8993(02)03153-0. [DOI] [PubMed] [Google Scholar] source
- Not checked — no full text of the sourcecites [16] Shen F, et al. 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment. Neuropharmacology. 2011;61:69–79. doi: 10.1016/j.neuropharm.2011.02.026. [DOI] [PubMed] [Google Scholar] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In contrast, infusion of NMDA, which can also activate ERK (29), significantly lowered ISF Aβ levels by over 50% (Fig. S3); this reduction was blocked by ERK and MEK inhibitors (31).”
What the sources say
- Supportedcites [31] Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR. Opposing synaptic regulation of amyloid-β metabolism by NMDA receptors in vivo. J Neurosci. 2011;31:11328–11337. doi: 10.1523/JNEUROSCI.0607-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Results section, “ERK signaling is required for NMDA-dependent depression of ISF Aβ levels,” reports that 40 μm NMDA no longer decreased ISF Aβ when either the MEK inhibitor PD98059 or the ERK inhibitor FR180204 was infused. This directly supports the attributed claim. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“chronic administration of selective serotonin reuptake inhibitors (SSRIs) reduces brain Aβ levels in mice (17–19).”
What the sources say
- Not checked — no full text of the sourcecites [17] Tucker S, et al. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Curr Alzheimer Res. 2006;3:221–227. doi: 10.2174/156720506777632835. [DOI] [PubMed] [Google Scholar] source
- Partly supportedcites [18] Nelson RL, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol. 2007;205:166–176. doi: 10.1016/j.expneurol.2007.01.037. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Results report that five months of paroxetine treatment reduced cortical Aβ1−40 levels in male and female 3xTgAD mice. The same section reports no significant effect on Aβ1−42; the study tested paroxetine, not SSRIs as a class. The claim therefore omits important limits on which Aβ level fell and which drug was studied. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [19] Pákáski M, et al. Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochem Int. 2005;47:190–195. doi: 10.1016/j.neuint.2005.03.004. [DOI] [PubMed] [Google Scholar] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In in vivo model systems, similar magnitudes of Aβ reductions are sufficient to prevent or halt Aβ plaque accumulation (53, 54).”
What the sources say
- Not checked — no full text of the sourcecites [53] McConlogue L, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem. 2007;282:26326–26334. doi: 10.1074/jbc.M611687200. [DOI] [PubMed] [Google Scholar] source
- Supportedcites [54] Yan P, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009;29:10706–10714. doi: 10.1523/JNEUROSCI.2637-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Results report that Compound E reduced ISF Aβ by 22–25% over 24 hours and suggest that this modest decrease may be sufficient to arrest plaque growth in vivo. In APP/PS1 mice, treatment suppressed existing-plaque growth and markedly attenuated new-plaque appearance. The paper does not claim that existing plaques regressed. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, infusion of NMDA, which can also activate ERK (29), significantly lowered ISF Aβ levels by over 50% (Fig. S3); this reduction was blocked by ERK and MEK inhibitors (31).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
59 more claims
Create a free account to see all 103 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Community volunteers treated with antidepressants over a period of 5 years (mean: 34.5 months) had significantly lower amyloid load in brain PET scans than those who had never received antidepressants118.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previously depressed patients who had undergone SSRI treatment in the five years preceding their enrollment in a positron emission tomography (PET) study to quantify amyloid binding, had less evidence of Aβ deposits than those who had not been exposed to SSRI treatment (13).”
From An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice (2014) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The length of antidepressant treatment prior to scanning correlated with lower plaque load.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [118]
The cited source says what the claim attributes to it.
In the citing paper
“Serotonin signaling suppresses generation of amyloid-β (Aβ) in vitro and in animal models of Alzheimer’s disease (AD).”
From An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice (2014) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Chronic SSRI treatment over the course of four months reduced Aβ plaque load by 50% in mice (13).”
From An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice (2014) · cites this paper as [13]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Results
“MCBP = 0.13 ± 0.019; Wilcoxon rank sum test P = 0.01”
§ Results
“MCBP mean (SD) 0.13 (0.2) 0.05 (0.2) −2.44 ‡ 0.02”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results
“These treated individuals had significantly lower mean cortical binding potential (MCBP) (0.06 ± 0.023)”
§ Results
“MCBP mean (SD) 0.13 (0.2) 0.05 (0.2) −2.44 ‡ 0.02”
Citations
Cites
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524 · cited 2×
“The dose of each SSRI administered in mice was within the range of what would be prescribed to human patients to treat depression (taking into account species differences in metabolism) (23).”
BackgroundImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644
Ownby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.530 · Cited by 1,493
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“Several anti-Aβ therapeutic strategies are being pursued to treat AD; however, it is likely that treatment will need to begin during the preclinical phase to prevent or limit plaque accumulation to be beneficial in reducing the risk of developing AD (51, 52).”
BackgroundSynaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265 · cited 2×
“TTX dramatically reduces neuronal activity and ISF Aβ levels in vivo (5).”
Self-citationUntreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Self-citation
Cited by
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
“As serotonin can reduce Aβ plaque formation and AD risk [580], GF conditions may modulate Aβ pathology through alterations in serotonin.”
BackgroundHistory and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Extracellular vesicles round off communication in the nervous system
Budnik, V., Ruiz-Cañada, C., & Wendler, F. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.29 · Cited by 712
Mechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592
Metadata
- Authors
- Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., Kim, J., Morris, J. C., Mintun, M. A., & Sheline, Y. I.
- Affiliations
- Washington University in St. Louis (US)
- Psychiatry,
- Departments of aNeurology,
- and eBiostatistics,
- Radiology,
- Eli Lilly (United States) (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-08-22
- Volume
- 108
- Issue
- 36
- Pages
- 14968-14973
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3169155
- OpenAlex
- W1977085392
- Cited by
- 377
- References
- 59
- Citations by year
- 2026: 20 · 2025: 32 · 2024: 37 · 2023: 22 · 2022: 30 · 2021: 33 · 2020: 31 · 2019: 26 · 2018: 31 · 2017: 24 · 2016: 29 · 2015: 12 · 2014: 19 · 2013: 19 · 2012: 9
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (and K24, 5p30ns069329-02, NS069329)
- U.S. Public Health Service (K24MHO79510)
- National Institute on Aging (K01AG029524, P50AG005681, P01AG003991)
- National Institute of Mental Health (R21MH077124, K24MH079510)
- National Institute of Neurological Disorders and Stroke (P30-NS069329)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- serotonin signaling, amyloid-beta, amyloid plaques, Alzheimer's disease, selective serotonin reuptake inhibitors, citalopram, ERK signaling, brain interstitial fluid, hippocampus, antidepressant use, Pittsburgh compound B, amyloid PET, transgenic mouse model, cognitively normal elderly
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Animals, Brain, Female, Humans, Male, Mice, Transgenic, Radiography, Serotonin, Thiazoles, Time Factors, Citalopram, Signal Transduction, Amyloid beta-Peptides, Antidepressive Agents, Second-Generation, Positron-Emission Tomography, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. https://app.cochat.ai/papers/10.1073/pnas.1107411108
- The paper
- Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., Kim, J., Morris, J. C., Mintun, M. A., & Sheline, Y. I. (2011). Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1107411108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.